Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript

Jennifer Good: Yes. And again, when we lay these studies out, we can get into that a little better. I would say in the IPF which is probably a little more advanced here, we — there’s a sort of accepted rate around 25%. We saw slightly lower, roughly 23% in our study. But when you look across the trials that have been done, that’s a pretty good estimate. I think in RCC, we’re working with sort of the experts here in the space who have all the data. David, I don’t know if you know the powering assumptions we’re using on placebo. You’ve been working on that protocol.

David Clark: Absolutely. And I just agree totally with what you said on the IPF. For the IPF, including recent studies, they’ve been below 30% for placebo response consistently. The RCC, the key there is that it’s a 2-way crossover design like CANAL. Now in RCC studies like that, including recent RCC studies, the placebo response has been around about 20%. So it’s not — it’s quite a different placebo response than has been seen in the longer-duration parallel group studies in RCC.

Operator: I’m not showing any further questions. This concludes our question-and-answer session. I would like to turn the call back over to Jennifer Good for closing remarks.

Jennifer Good: We would like to thank everybody for participating in today’s call and hope to talk with some of you at the Needham Investor Conference being held April 17 through April 20 virtually. Thank you.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.